



## Monica Donno

study nurse

Medizinische Onkologie und Hämatologie · Dept. I

### Contact

Monica Donno  
Rorschacherstrasse 95  
9007 St. Gallen

T +41 71 494 7215  
Monica.Donno@kssg.ch

### Units

Medizinische Onkologie und Hämatologie

### Profile Function

study nurse

## Publications (0)

No results found.

## Projects (6)

### **AMG 355 20220028**

*Clinical Studies - Oct 17, 2024 - Dec 31, 2028*

*Ongoing*

### **A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors**

*Clinical Studies - Feb 1, 2023 - Dec 31, 2028*

*Ongoing*

### **A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors**

*Clinical Studies - Jan 11, 2023 - Dec 31, 2028*

*Ongoing*

### **A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy**

*Clinical Studies - Sep 16, 2022 - Dec 31, 2032*

*Ongoing*

### **A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors**

*Clinical Studies - Jan 13, 2022 - Mar 2, 2027*

*Ongoing*

### **MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)**

*Clinical Studies - Mar 17, 2021 - May 7, 2030*

*Ongoing*